Edward Scolnick

Attachments

1982 Scolnick joined Merck in 1982 as executive director of virus and cell biology, after being recruited from the National Institutes of Health.
1982-2002 While at Merck, he was involved in the development and introduction of 29 new medications and vaccines.
2020 WSJ - The Secret Group of Scientists and Billionaires Pushing a Manhattan Project for Covid-19
He was a key figure in the development and marketing of Vioxx, which was pulled from the market after it was discovered that the drug caused a dangerously high risk of myocardial infarction.
In the subsequent investigations, it was revealed that it was likely that Merck knew about the adverse effects of the drug, and Scolnick had dismissed them in order to push the drug to market before Bayer's Celebrex.
Investigations revealed that Merck had several years worth of information suggesting an elevated risk of cardiac events, and Vice President Edward Scolnick took much of the blame for the suppression of this information.
Legal claims resulting from this have cost Merck billions. During the five years it was available in the US, more than 38,000 deaths were related to Vioxx use, and up to 25 million Americans took the drug.
Ras GTPase
Rofecoxib (Vioxx, Ceoxx, and Ceeoxx)